- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07459634
En studie av lurbinectedin i kombinasjon med durvalumab for behandling av deltakere med ES-SCLC
En fase 2, multikenter, åpen merket, enarmsstudie av lurbinectedin i kombinasjon med durvalumab som førstelinje vedlikeholdsterapi hos deltakere med omfattende småcellet lungekreft etter induksjonsbehandling med platina-basert kjemoterapi og durvalumab
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The study will evaluate the safety and efficacy of lurbinectedin in combination with durvalumab as maintenance therapy in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen. In order to be considered for eligibility screening for the maintenance phase, participants need to have an ongoing CR, PR, or stable disease (SD) per RECIST v1.1 criteria after completion of 4 cycles of platinum plus etoposide containing regimen with at least 3 cycles of durvalumab during induction treatment.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trial Disclosure & Transparency
- Telefonnummer: 215-832-3750
- E-post: ClinicalTrialDisclosure@JazzPharma.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90067
- Rekruttering
- Valkyrie Clinical Trials, Inc.
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32256
- Rekruttering
- Cancer Specialists of North Florida
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40503
- Rekruttering
- Baptist Health
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64132
- Rekruttering
- MidAmerica Cancer Centre
-
-
South Carolina
-
Rock Hill, South Carolina, Forente stater, 29732
- Rekruttering
- Carolina Blood and Cancer Care
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
- Participant has received 4 cycles of definitive platinum-based chemotherapy with at least 3 cycles of durvalumab
- Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.
- Adequate hematologic and end-organ function for at least 7 days prior to dosing.
- Has a body weight > 30 kg.
- Adequate contraceptive precautions.
Exclusion Criteria:
- Clinically confirmed leptomeningeal carcinomatosis.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- Significant cardiovascular disease within 3 months prior to enrollment
- History of another primary malignancy
- Presence or history of Central Nervous System (CNS) metastases
- History of allogeneic organ transplantation.
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan.
- Any concurrent chemotherapy, study intervention, biologic, or hormonal therapy for cancer treatment.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention.
- Pregnant or breastfeeding or intending to become pregnant during the study or within 6 months after the last dose of study intervention.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Durvalumab and lurbinectedin treatment arm
Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen. |
Administered by intravenous (IV) infusion
Andre navn:
Administered by intravenous (IV) infusion
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Investigator assessed PFS rate
Tidsramme: 6 months
|
Progression Free Survival (PFS) rate is the proportion of participants who have not experienced disease progression (as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) or death from any cause |
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall deltakere som krever doseendring
Tidsramme: Opptil 2 år
|
Opptil 2 år
|
|
|
Antall deltakere som krever avbrudd av noen komponent i kombinasjonsterapien
Tidsramme: Opptil 2 år
|
Opptil 2 år
|
|
|
Plasmakonsentrasjoner av lurbinectedin
Tidsramme: Opptil 3 måneder
|
Opptil 3 måneder
|
|
|
Investigator assessed PFS
Tidsramme: Up to 2 years
|
PFS is defined as the time from the start of maintenance treatment until the first documentation of disease progression (as determined by the investigator according to RECIST v1.1) or death due to any cause, whichever occurs first. |
Up to 2 years
|
|
Investigator-assessed confirmed ORR
Tidsramme: Up to 2 years
|
Confirmed Objective Response Rate (ORR) is the proportion of participants with Complete Response (CR) or Partial Response (PR) on 2 consecutive occasions ≥ 4 weeks apart, after the start of maintenance treatment, as determined by the investigator according to RECIST v1.1. |
Up to 2 years
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: First dose to 90 days after last dose (Up to 2 years)
|
Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 or higher |
First dose to 90 days after last dose (Up to 2 years)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- JZP712-203
- 2025-524566-13-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .